The API has been demonstrated to substantially decrease yes-associated protein - transcriptional co-activator with PDZ-binding motif (YAP/TAZ) activity and downregulate the expression of target genes, including connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61), in triple negative breast cancer (TNBC) stem cells (Li et al., 2018). The gene discussed is CCN1; the disease is triple-negative breast carcinoma.